- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Lixte Biotechnology files to sell 5.26M shares of common stock, warrants | 2 | Seeking Alpha | ||
| 18.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 17.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 04.04. | Lixte Biotechnology files to sell 467,393 shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
| 04.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 31.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 | 1 | GlobeNewswire (USA) | ||
| 27.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer | 146 | GlobeNewswire (Europe) | -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with... ► Artikel lesen | |
| 24.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 11.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer | 1 | GlobeNewswire (USA) | ||
| 21.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 13.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.02. | LIXTE Biotechnology announces $1.05M registered direct offering; shares fall | 3 | Seeking Alpha | ||
| 11.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| IMMUNITYBIO | 2,300 | -0,09 % | ImmunityBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MARINOMED BIOTECH | 18,300 | +2,52 % | Marinomed Biotech-Aktie // Entscheidende Partnerschaft - GBC mit Kauf-Rating | Marinomed Biotech hat Anfang Juni eine Vereinbarung mit einem Schweizer Pharmaunternehmen zur Entwicklung und Vermarktung von Budesolv in der Schweiz bekanntgegeben. Diese Partnerschaft sei ein zentraler... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ORAGENICS | 4,060 | +14,85 % | ORAGENICS INC - S-1, General form for registration of securities | ||
| CAPRICOR | 9,560 | +0,10 % | B.Riley initiates Capricor Therapeutics stock with buy rating | ||
| FIBROGEN | 5,230 | -1,32 % | XFRA 1FG0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFIBROGEN INC. NEW... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | -81,82 % | Revive Therapeutics Ltd: Revive hopes to conclude bucillamine study by September | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| RADIUS HEALTH | - | - | +850% CVR-Jackpot: Biotech-Tipp Radius Health beschert Anlegern Geldsegen | Der Optionsvoodoo-Chatraum von sharedealsPlus brummte letzte Woche vor Begeisterung, denn ein längst vergessener Trade sorgt für Jubelstürme und prall gefüllte Konten bei den Mitgliedern des Anlegerclubs... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,100 | -2,65 % | Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma | Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive... ► Artikel lesen | |
| COCRYSTAL | 1,240 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants | Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,068 (-8,74 %) liegt der Kurs bei 0,715 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.